The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VT-1598, a novel oral agent for the treatment of coccidioidomycosis, also known as Valley Fever, according to Viamet Pharmaceuticals...

The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1129, a novel candidate for the treatment of cryptococcal meningitis, according to...

Viamet Pharmaceuticals announced Thursday that VT-1129, a potent and selective, oral, antifungal agent, has been granted orphan drug designation by the U.S. Food & Drug Administration (FDA) for the...